NasdaqGS:KNSA

Stock Analysis Report

Executive Summary

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Kiniksa Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KNSA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.6%

KNSA

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

8.8%

KNSA

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: KNSA underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: KNSA underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

KNSAIndustryMarket
7 Day10.6%0.7%-1.1%
30 Day31.1%5.6%1.4%
90 Day80.7%6.2%6.9%
1 Year8.8%8.8%14.9%14.0%20.3%17.9%
3 Yearn/a24.4%21.1%47.8%38.3%
5 Yearn/a3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Kiniksa Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kiniksa Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KNSA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KNSA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KNSA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: KNSA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KNSA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KNSA is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Kiniksa Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

18.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNSA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNSA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNSA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if KNSA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KNSA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KNSA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Kiniksa Pharmaceuticals performed over the past 5 years?

-85.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: KNSA is currently unprofitable.

Growing Profit Margin: KNSA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if KNSA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare KNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: KNSA has a negative Return on Equity (-68.54%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Kiniksa Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: KNSA's short term assets ($268.3M) exceed its short term liabilities ($27.6M).

Long Term Liabilities: KNSA's short term assets ($268.3M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: KNSA is debt free.

Reducing Debt: KNSA has not had any debt for past 5 years.


Balance Sheet

Inventory Level: KNSA has a low level of unsold assets or inventory.

Debt Coverage by Assets: KNSA's debt is not covered by short term assets (assets are -6.042479620043E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KNSA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KNSA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -61.1% each year


Next Steps

Dividend

What is Kiniksa Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate KNSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KNSA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KNSA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KNSA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KNSA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Sanj Patel (49yo)

4.6yrs

Tenure

US$7,308,557

Compensation

Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 a ...


CEO Compensation Analysis

Compensation vs Market: Sanj's total compensation ($USD7.31M) is above average for companies of similar size in the US market ($USD2.51M).

Compensation vs Earnings: Sanj's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sanj Patel
CEO & Chairman of the Board4.6yrsUS$7.31m3.43% $36.1m
John Paolini
Senior VP & Chief Medical Officer3.5yrsUS$2.50m0.033% $345.1k
Chris Heberlig
Executive VP4.6yrsno data0.95% $10.0m
Thomas Beetham
Executive VP of Corporate Development & Operations0.3yrsno data0.90% $9.5m
Michael Megna
Chief Accounting Officer & VP of Finance0yrsno datano data
Mark Ragosa
Vice President of Investor Relations0yrsno datano data
Melissa Manno
Vice President of of Human Resources0yrsno datano data
Rasmus Holm-Jorgensen
Senior VP0yrsno data0.74% $7.8m
Carsten Boess
Executive Vice President of Corporate Affairs0yrsno data1.01% $10.6m
Christine Maurer
Senior Vice President of Program Management0yrsno datano data

4.0yrs

Average Tenure

49yo

Average Age

Experienced Management: KNSA's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sanj Patel
CEO & Chairman of the Board4.6yrsUS$7.31m3.43% $36.1m
Kimberly Popovits
Independent Director2yrsUS$345.25kno data
Felix Baker
Lead Director4.3yrsUS$258.35k0.027% $284.5k
Thomas Malley
Independent Director3.2yrsUS$170.14kno data
Barry Quart
Independent Director4.3yrsUS$166.35kno data
Richard Levy
Independent Director0.9yrsno datano data
Stephen Biggar
Independent Director4.3yrsUS$241.72kno data
Robert Desnick
Chairman of Scientific Advisory Board0yrsno data1.69% $17.8m
Tracey Mccain
Independent Director2yrsUS$346.71kno data

3.8yrs

Average Tenure

50.5yo

Average Age

Experienced Board: KNSA's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 192.7%.


Top Shareholders

Company Information

Kiniksa Pharmaceuticals, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kiniksa Pharmaceuticals, Ltd.
  • Ticker: KNSA
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.052b
  • Shares outstanding: 54.88m
  • Website: https://www.kiniksa.com

Number of Employees


Location

  • Kiniksa Pharmaceuticals, Ltd.
  • Clarendon House
  • 2 Church Street
  • Hamilton
  • HM 11
  • Bermuda

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KNSANasdaqGS (Nasdaq Global Select)YesClass A Common SharesUSUSDMay 2018

Biography

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company’s preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 02:01
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.